Physician profile
Vijay Adimoolam
NPI 1588693857
$3,313.07
in general payments reported to CMS, 2019-2025
20 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $221 · 2021: $292 · 2022: $826 · 2023: $1,088 · 2024: $580 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,791.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,256.98 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Janssen Biotech, INC. | $479.33 | 2021-2024 | Stelara |
| Celgene Corporation | $424.20 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $293.99 | 2019-2024 | Entyvio |
| Genzyme Corporation | $127.67 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.44 | 2022-2024 | Trulance, Xifaxan |
| Pfizer INC. | $79.56 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $62.79 | 2022-2023 | Dupixent |
| Lilly USA, LLC | $51.95 | 2024 | Omvoh |
| Olympus America INC. | $51.89 | 2019-2020 | |
| Ardelyx, INC. | $45.70 | 2022-2023 | Ibsrela |
| Daiichi Sankyo INC. | $45.43 | 2024 | Injectafer |
| Qol Medical, LLC | $34.75 | 2023 | Sucraid |
| Braintree Laboratories, INC. | $32.29 | 2023 | Sutab, Suflave |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $26.51 | 2023 | Idacio |
| Ferring Pharmaceuticals INC. | $19.43 | 2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $17.03 | 2019 | |
| Merck Sharp & Dohme LLC | $13.13 | 2021 | |
| Boston Scientific Corporation | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vijay Adimoolam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.